Autologous Cell Therapy Manufacturing CDMOs in United States
10 published
10 published CDMOs match Autologous Cell Therapy Manufacturing in United States.
Locations in this set include United States, China, Japan, United Kingdom, Belgium, and Canada.
Capabilities that show up most often in this set: Cell Therapy, Gene Therapy, Biologics (Monoclonal Antibodies), Biologics (Other), and AAV / Viral Vector Platform.
Matching companies
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
CellaresCellares operates a global network of Smart Factories delivering integrated development and manufacturing (IDMO) services for cell therapies, with proprietary Cell Shuttle® and Cell Q™ platforms enabling cGMP-compliant, automated manufacturing and quality control at clinical and commercial scale.
Cellipont BioservicesCellipont Bioservices is a cell therapy CDMO offering end-to-end development, analytical, and cGMP manufacturing services for autologous, allogeneic, CAR-T, and iPSC-derived therapies from preclinical through commercial stages.
Minaris Advanced TherapiesPure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
PluriFull-service CDMO specializing in cell therapy manufacturing with GMP facilities, proprietary packed-bed expansion technology, and regulatory approvals from FDA, EMA, PMDA, and other key agencies for clinical-stage production.
Porton AdvancedEnd-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
RoslinCTRoslinCT is a cell and gene therapy CDMO offering cGMP iPSC banking, process and analytical development, and clinical and commercial manufacturing for autologous and allogeneic programs.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /services/autologous-cell-therapy-manufacturing/us.md